Why Is AMYLYX PHARMACEUTICA (AMLX) Stock Moving Today?

AMLX stock is moving higher today amid renewed investor interest driven by a combination of analyst upgrades and recent clinical developments. The stock has surged 15.7% following topline results from the Phase 3 LUCIDITY trial of avexitide, which were released on August 18, 2026. Analysts at LifeSci Capital, Mizuho, Guggenheim, and Baird have all maintained or raised their ratings and price targets in the past week, signaling optimism about the company’s prospects.

What Happened

Amylyx Pharmaceuticals has been in the spotlight after releasing data from its Phase 3 LUCIDITY trial of avexitide, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). The trial results, though not yet fully detailed, have triggered a sharp rise in the stock. This follows an upsized $500 million public offering of 14,090,000 common shares at $35.50 per share, which was announced earlier. The offering has added liquidity to the stock and attracted attention from analysts and investors alike. LifeSci Capital analyst Rami Katkhuda reiterated a Buy rating, while Mizuho, Guggenheim, and Baird raised their price targets to $42, $55, and $52 respectively. These actions reflect a growing confidence in the company’s pipeline and strategic moves.

What The Data Shows

The stock has surged 69.6% over the last eight sessions, climbing from $23.35 to $39.61. On August 24, 2026, AMLX printed 22 fresh 52-week highs and five fresh 52-week lows, indicating broad participation and volatility. The stock closed Monday at $21.43 but traded as high as $24.80 after the trial results were released. Insider activity has been limited, with one sale reported in the last 90 days totaling $539,000. The company remains unprofitable, with a trailing twelve-month revenue decline of 100.3% and an EPS of -1.43. Despite this, the market cap has expanded to $4.3 billion.

What To Watch

Investors should monitor the full details of the Phase 3 LUCIDITY trial results, which will be critical in determining the next phase of development for avexitide. The biotech sector will also be watching for broader coverage from additional analysts and institutional investors.